Eurofins Scientific SE
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection,… Read more
Eurofins Scientific SE (ERFSF) - Total Assets
Latest total assets as of December 2025: $10.98 Billion USD
Based on the latest financial reports, Eurofins Scientific SE (ERFSF) holds total assets worth $10.98 Billion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eurofins Scientific SE - Total Assets Trend (2002–2025)
This chart illustrates how Eurofins Scientific SE’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eurofins Scientific SE - Asset Composition Analysis
Current Asset Composition (December 2025)
Eurofins Scientific SE's total assets of $10.98 Billion consist of 24.2% current assets and 75.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.2% |
| Accounts Receivable | $1.54 Billion | 14.0% |
| Inventory | $138.95 Million | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $689.74 Million | 6.3% |
| Goodwill | $4.66 Billion | 42.4% |
Asset Composition Trend (2002–2025)
This chart illustrates how Eurofins Scientific SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eurofins Scientific SE's current assets represent 24.2% of total assets in 2025, a decrease from 40.7% in 2002.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2025, up from -1.8% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 31.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 42.4% of total assets.
Eurofins Scientific SE Competitors by Total Assets
Key competitors of Eurofins Scientific SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
Optipharm.CO.LTD
KQ:153710
|
Korea | ₩42.32 Billion |
|
Bionet
TWO:1784
|
Taiwan | NT$3.10 Billion |
Eurofins Scientific SE - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Eurofins Scientific SE generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Eurofins Scientific SE generates $ 4.32 in net profit.
Eurofins Scientific SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.16 | 1.48 |
| Quick Ratio | 1.03 | 1.09 | 1.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $222.92 Million | $ 342.00 Million | $ 821.80 Million |
Eurofins Scientific SE - Advanced Valuation Insights
This section examines the relationship between Eurofins Scientific SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.54 |
| Latest Market Cap to Assets Ratio | 0.55 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | $10.98 Billion |
| Market Capitalization | $6.09 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Eurofins Scientific SE's assets below their book value (0.55 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Eurofins Scientific SE's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Eurofins Scientific SE (2002–2025)
The table below shows the annual total assets of Eurofins Scientific SE from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.98 Billion | +0.85% |
| 2024-12-31 | $10.89 Billion | 0.00% |
| 2023-12-31 | $10.89 Billion | +7.98% |
| 2022-12-31 | $10.08 Billion | +8.05% |
| 2021-12-31 | $9.33 Billion | +8.83% |
| 2020-12-31 | $8.58 Billion | +9.62% |
| 2019-12-31 | $7.82 Billion | +8.57% |
| 2018-12-31 | $7.21 Billion | +23.54% |
| 2017-12-31 | $5.83 Billion | +41.24% |
| 2016-12-31 | $4.13 Billion | +11.61% |
| 2015-12-31 | $3.70 Billion | +97.52% |
| 2014-12-31 | $1.87 Billion | +25.13% |
| 2013-12-31 | $1.50 Billion | +29.15% |
| 2012-12-31 | $1.16 Billion | +7.87% |
| 2011-12-31 | $1.07 Billion | +45.97% |
| 2010-12-31 | $736.16 Million | +11.66% |
| 2009-12-31 | $659.30 Million | -10.18% |
| 2008-12-31 | $734.01 Million | +19.93% |
| 2007-12-31 | $612.02 Million | +32.95% |
| 2006-12-31 | $460.34 Million | +72.95% |
| 2005-12-31 | $266.16 Million | +39.99% |
| 2004-12-31 | $190.12 Million | +14.20% |
| 2003-12-31 | $166.48 Million | +3.88% |
| 2002-12-31 | $160.26 Million | -- |